Progress and challenges in the development of a cell-based therapy for hemophilia A

Journal of Thrombosis and Haemostasis

Volumn 12, Issue 12, 2014, Pages 1954-1965

  Fomin, M E ^a,b   Togarrati, P P ^a,b   Muench, M O ^a,b,c  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b University of California   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cell and tissue based therapy endothelial cells; Factor VIII; Fetal stem cells; Hemophilia A; Pluripotent stem cells

Indexed keywords

BLOOD CLOTTING FACTOR 8;

BIOLOGICAL THERAPY; BLOOD DONOR; BONE MARROW CELL; CELL THERAPY; CELL TRANSPLANTATION; CLINICAL EFFECTIVENESS; EMBRYO DEVELOPMENT; EMBRYONIC STEM CELL; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; ENGRAFTMENT; FETUS (ANATOMY); FETUS LIVER; GRAFT REJECTION; HEMOPHILIA A; HOST RESISTANCE; HUMAN; IMMUNE DEFICIENCY; LIVER; LIVER SINUSOIDAL ENDOTHELIAL CELL; NONHUMAN; PLURIPOTENT STEM CELL; REVIEW; ANIMAL; CYTOLOGY; MALE; MOUSE; PIG; PROCEDURES; RAT; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; EMBRYONIC STEM CELLS; ENDOTHELIAL CELLS; HEMOPHILIA A; HUMANS; MALE; MICE; PLURIPOTENT STEM CELLS; RATS; STEM CELL RESEARCH; STEM CELL TRANSPLANTATION; SWINE;

EID: 84916613393     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12750     Document Type: Review

References (83)

1. Rosendaal FR, Smit C, Briët E. Hemophilia treatment in historical perspective: a review of medical and social developments. Ann Hematol 1991; 62: 5-15.
2. Franchini M, Mannucci PM. The history of hemophilia. Semin Thromb Hemost 2014; 40: 571-6.
3. Ingram I. The history of haemophilia. J Clin Pathol 1976; 29: 469-79.
4. Mannucci PM, Franchini M. Haematology clinic: haemophilia A. Hematology 2014; 19: 181-2.
5. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011; 82: 91-8.
6. Lane S. Haemorrhagic diathesis: successful transfusion of blood. Lancet 1840; 35: 185-8.
7. Pool JG, Gershgold EJ, Pappenhagen AR. High-potency antihaemophilic factor concentrate prepared from cryoglobulin precipitate. Nature 1964; 203: 312.
8. Webster WP, Roberts HR, Thelin GM, Wagner RH, Brinkhous KM. Clinical use of a new glycine-precipitated antihemophilic fraction. Am J Med Sci 1965; 250: 643-51.
9. Brinkhous KM, Shanbrom E, Roberts HR, Webster WP, Fekete L, Wagner RH. A new high-potency glycine-precipitated antihemophilic factor (AHF) concentrate. Treatment of classical hemophilia and hemophilia with inhibitors. JAMA 1968; 205: 613-7.
10. Gitschier J, Wood WI, Goralka TM, Wion KL, Chen EY, Eaton DH, Vehar GA, Capon DJ, Lawn RM. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
11. Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD, Kaufman RJ, Brown E, Shoemaker C, Orr EC, Amphlett GW, Foster WB, Coe ML, Knutson GJ, Fass DN, Hewick RM. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
12. Wood WI, Capon DJ, Simonsen CC, Eaton DL, Gitschier J, Keyt B, Seeburg PH, Smith DH, Hollingshead P, Wion KL, Delwart E, Tuddenham EG, Vehar GA, Lawn RM. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7.
13. Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, van Geet C, Kenet G, Mäkipernaa A, Molinari AC, Muntean W, Kobelt R, Rivard G, Santagostino E, Thomas A, van den Berg HM, PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
14. Fitch K, Pyenson B. Benefit designs for high cost medical conditions. Milliman Research Report. New York, NY: Milliman, Inc., 2011: 1-24.
15. Chuah MK, Evens H, VandenDriessche T. Gene therapy for hemophilia. J Thromb Haemost 2013; 11(Suppl 1): 99-110.
16. Moayeri M, Ramezani A, Morgan RA, Hawley TS, Hawley RG. Sustained phenotypic correction of hemophilia a mice following oncoretroviral-mediated expression of a bioengineered human factor VIII gene in long-term hematopoietic repopulating cells. Mol Ther 2004; 10: 892-902.
17. Moayeri M, Hawley TS, Hawley RG. Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol Ther 2005; 12: 1034-42.
18. Du LM, Nurden P, Nurden AT, Nichols TC, Bellinger DA, Jensen ES, Haberichter SL, Merricks E, Raymer RA, Fang J, Koukouritaki SB, Jacobi PM, Hawkins TB, Cornetta K, Shi Q, Wilcox DA. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013; 4: 2773.
19. Wang Q, Gong X, Gong Z, Ren X, Ren Z, Huang S, Zeng Y. The mesenchymal stem cells derived from transgenic mice carrying human coagulation factor VIII can correct phenotype in hemophilia A mice. J Genet Genomics 2013; 40: 617-28.
20. Wells KE, Maule J, Kingston R, Foster K, McMahon J, Damien E, Poole A, Wells DJ. Immune responses, not promoter inactivation, are responsible for decreased long-term expression following plasmid gene transfer into skeletal muscle. FEBS Lett 1997; 407: 164-8.
21. High KH, Nathwani A, Spencer T, Lillicrap D. Current status of haemophilia gene therapy. Haemophilia 2014; 20(Suppl 4): 43-9.
22. Powell JS, Ragni MV, White GC, Lusher JM, Hillman-Wiseman C, Moon TE, Cole V, Ramanathan-Girish S, Roehl H, Sajjadi N, Jolly DJ, Hurst D. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003; 102: 2038-45.
23. Wion KL, Kelly D, Summerfield JA, Tuddenham EG, Lawn RM. Distribution of factor VIII mRNA and antigen in human liver and other tissues. Nature 1985; 317: 726-9.
24. Lenting PJ, van Mourik JA, Mertens K. The life cycle of coagulation factor VIII in view of its structure and function. Blood 1998; 92: 3983-96.
25. Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE. Animal models of hemophilia. Prog Mol Biol Transl Sci 2012; 105: 151-209.
26. Christopherson PW, Bacek LM, King KB, Boudreaux MK. Two novel missense mutations associated with hemophilia A in a family of boxers, and a German shepherd dog. Vet Clin Pathol 2014; 43: 312-6.
27. Lozier JN, Dutra A, Pak E, Zhou N, Zheng Z, Nichols TC, Bellinger DA, Read M, Morgan RA. The Chapel Hill hemophilia A dog colony exhibits a factor VIII gene inversion. Proc Natl Acad Sci U S A 2002; 99: 12991-6.
28. Webster WP, Zukoski CF, Hutchin P, Reddick RL, Mandel SR, Penick GD. Plasma factor VIII synthesis and control as revealed by canine organ transplantation. Am J Physiol 1971; 220: 1147-54.
29. Ko S, Tanaka I, Kanokogi H, Kanehiro H, Okayama J, Ori J, Shima M, Yoshioka A, Giles A, Nakajima Y. Efficacy of auxiliary partial orthotopic liver transplantation for cure of hemophilia in a canine hemophilia A model. Transplant Proc 2005; 37: 1131-3.
30. Ko S, Tanaka I, Kanehiro H, Kanokogi H, Ori J, Shima M, Yoshioka A, Giles A, Nakajima Y. Preclinical experiment of auxiliary partial orthotopic liver transplantation as a curative treatment for hemophilia. Liver Transpl 2005; 11: 579-84.
31. Stel HV, van der Kwast TH, Veerman EC. Detection of factor VIII/coagulant antigen in human liver tissue. Nature 1983; 303: 530-2.
32. Zelechowska MG, van Mourik JA, Brodniewicz-Proba T. Ultrastructural localization of factor VIII procoagulant antigen in human liver hepatocytes. Nature 1985; 317: 729-30.
33. Do H, Healey JF, Waller EK, Lollar P. Expression of factor VIII by murine liver sinusoidal endothelial cells. J Biol Chem 1999; 274: 19587-92.
34. Kumaran V, Benten D, Follenzi A, Joseph B, Sarkar R, Gupta S. Transplantation of endothelial cells corrects the phenotype in hemophilia A mice. J Thromb Haemost 2005; 3: 2022-31.
35. Fomin ME, Zhou Y, Beyer AI, Publicover J, Baron JL, Muench MO. Production of factor VIII by human liver sinusoidal endothelial cells transplanted in immunodeficient uPA mice. PLoS One 2013; 8: e77255.
36. Shahani T, Covens K, Lavend'homme R, Jazouli N, Sokal E, Peerlinck K, Jacquemin M. Human liver sinusoidal endothelial cells but not hepatocytes contain factor VIII. J Thromb Haemost 2014; 12: 36-42.
37. Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014; 123: 3706-13.
38. Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014; 123: 3697-705.
39. Sródka A, Gryglewski RW, Szczepariski W. Browicz or Kupffer cells? Pol J Pathol 2006; 57: 183-5.
40. Follenzi A, Raut S, Merlin S, Sarkar R, Gupta S. Role of bone marrow transplantation for correcting hemophilia A in mice. Blood 2012; 119: 5532-42.
41. Follenzi A, Benten D, Novikoff P, Faulkner L, Raut S, Gupta S. Transplanted endothelial cells repopulate the liver endothelium and correct the phenotype of hemophilia A mice. J Clin Invest 2008; 118: 935-45.
42. Filali EE, Hiralall J, van Veen HA, Stolz DB, Seppen J. Human liver endothelial cells, but not macrovascular or microvascular endothelial cells engraft in the mouse liver. Cell Transplant 2012; 22: 1801-11.
43. Parent R, Durantel D, Sallé A, Lahlali T, DaCosta D, Plissonnier ML, Lesca G, Zoulim F, Marion MJ, Bartosch B. An immortalized human liver endothelial sinusoidal cell line for the study of the pathobiology of the liver endothelium. Biochem Biophys Res Commun 2014; 450: 7-12.
44. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest 2000; 105: 71-7.
45. Lin Y, Chang L, Solovey A, Healey JF, Lollar P, Hebbel RP. Use of blood outgrowth endothelial cells for gene therapy for hemophilia A. Blood 2002; 99: 457-62.
46. Tatsumi K, Sugimoto M, Lillicrap D, Shima M, Ohashi K, Okano T, Matsui H. A novel cell-sheet technology that achieves durable factor VIII delivery in a mouse model of hemophilia A. PLoS One 2013; 8: e83280.
47. Harb R, Xie G, Lutzko C, Guo Y, Wang X, Hill CK, Kanel GC, DeLeve LD. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury. Gastroenterology 2009; 137: 704-12.
48. Wang L, Wang X, Xie G, Wang L, Hill CK, DeLeve LD. Liver sinusoidal endothelial cell progenitor cells promote liver regeneration in rats. J Clin Invest 2012; 122: 1567-73.
49. Wang L, Wang X, Wang L, Chiu JD, van de Ven G, Gaarde WA, Deleve LD. Hepatic vascular endothelial growth factor regulates recruitment of rat liver sinusoidal endothelial cell progenitor cells. Gastroenterology 2012; 143: 1555-63.e2.
50. Muench MO, Beyer AI, Fomin ME, Thakker R, Mulvaney US, Nakamura M, Suemizu H, Bárcena A. The adult livers of immunodeficient mice support human hematopoiesis: evidence for a hepatic mast cell population that develops early in human ontogeny. PLoS One 2014; 9: e97312.
51. Suemizu H, Hasegawa M, Kawai K, Taniguchi K, Monnai M, Wakui M, Suematsu M, Ito M, Peltz G, Nakamura M. Establishment of a humanized model of liver using NOD/Shi-scid IL2Rgnull mice. Biochem Biophys Res Commun 2008; 377: 248-52.
52. Sandgren EP, Palmiter RD, Heckel JL, Daugherty CC, Brinster RL, Degen JL. Complete hepatic regeneration after somatic deletion of an albumin-plasminogen activator transgene. Cell 1991; 66: 245-56.
53. Mohammed FF, Khokha R. Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol 2005; 15: 555-63.
54. Muench MO. In utero transplantation: baby steps towards an effective therapy. Bone Marrow Transplant 2005; 35: 537-47.
55. Mychaliska GB, Muench MO, Rice HE, Leavitt AD, Cruz J, Harrison MR. The biology and ethics of banking fetal liver hematopoietic stem cells for in utero transplantation. J Pediatr Surg 1998; 33: 394-9.
56. Golfier F, Bárcena A, Cruz J, Harrison M, Muench M. Mid-trimester fetal livers are a rich source of CD34+/++ cells for transplantation. Bone Marrow Transplant 1999; 24: 451-61.
57. Khan AA, Habeeb A, Parveen N, Naseem B, Babu RP, Capoor AK, Habibullah CM. Peritoneal transplantation of human fetal hepatocytes for the treatment of acute fatty liver of pregnancy: a case report. Trop Gastroenterol 2004; 25: 141-3.
58. Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao P, Pande G, Narusu ML, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Management of hyperbilirubinemia in biliary atresia by hepatic progenitor cell transplantation through hepatic artery: a case report. Transplant Proc 2008; 40: 1153-5.
59. Khan AA, Shaik MV, Parveen N, Rajendraprasad A, Aleem MA, Habeeb MA, Srinivas G, Raj TA, Tiwari SK, Kumaresan K, Venkateswarlu J, Pande G, Habibullah CM. Human fetal liver-derived stem cell transplantation as supportive modality in the management of end-stage decompensated liver cirrhosis. Cell Transplant 2010; 19: 409-18.
60. Gridelli B, Vizzini G, Pietrosi G, Luca A, Spada M, Gruttadauria S, Cintorino D, Amico G, Chinnici C, Miki T, Schmelzer E, Conaldi PG, Triolo F, Gerlach JC. Efficient human fetal liver cell isolation protocol based on vascular perfusion for liver cell-based therapy and case report on cell transplantation. Liver Transpl 2012; 18: 226-37.
61. Wang JJ, Kuang Y, Zhang LL, Shen CL, Wang L, Lu SY, Lu XB, Fei J, Gu MM, Wang ZG. Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic stem cell therapy. Genet Mol Res 2013; 12: 1511-21.
62. Xu D, Alipio Z, Fink LM, Adcock DM, Yang J, Ward DC, Ma Y. Phenotypic correction of murine hemophilia A using an iPS cell-based therapy. Proc Natl Acad Sci U S A 2009; 106: 808-13.
63. Yakura Y, Ishihara C, Kurosaki H, Kazuki Y, Komatsu N, Okada Y, Doi T, Takeya H, Oshimura M. An induced pluripotent stem cell-mediated and integration-free factor VIII expression system. Biochem Biophys Res Commun 2013; 431: 336-41.
64. Park CY, Kim J, Kweon J, Son JS, Lee JS, Yoo JE, Cho SR, Kim JH, Kim JS, Kim DW. Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using talens. Proc Natl Acad Sci U S A 2014; 111: 9253-8.
65. Urnov FD, Miller JC, Lee YL, Beausejour CM, Rock JM, Augustus S, Jamieson AC, Porteus MH, Gregory PD, Holmes MC. Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature 2005; 435: 646-51.
66. Cong L, Ran FA, Cox D, Lin S, Barretto R, Habib N, Hsu PD, Wu X, Jiang W, Marraffini LA, Zhang F. Multiplex genome engineering using CRISPR/Cas systems. Science 2013; 339: 819-23.
67. Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, Kan YW. Seamless gene correction of β-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res 2014; 24: 1526-33.
68. Ye L, Wang J, Beyer AI, Teque F, Cradick TJ, Qi Z, Chang JC, Bao G, Muench MO, Yu J, Levy JA, Kan YW. Seamless modification of wild-type induced pluripotent stem cells to the natural CCR5Δ32 mutation confers resistance to HIV infection. Proc Natl Acad Sci U S A 2014; 111: 9591-6.
69. Ye L, Muench MO, Fusaki N, Beyer AI, Wang J, Qi Z, Yu J, Kan YW. Blood cell-derived induced pluripotent stem cells free of reprogramming factors generated by Sendai viral vectors. Stem Cells Transl Med 2013; 2: 558-66.
70. Merling RK, Sweeney CL, Choi U, De Ravin SS, Myers TG, Otaizo-Carrasquero F, Pan J, Linton G, Chen L, Koontz S, Theobald NL, Malech HL. Transgene-free ipscs generated from small volume peripheral blood nonmobilized CD34+ cells. Blood 2013; 121: e98-107.
71. Tan HK, Toh CX, Ma D, Yang B, Liu TM, Lu J, Wong CW, Tan TK, Li H, Syn C, Tan EL, Lim B, Lim YP, Cook SA, Loh YH. Human finger-prick induced pluripotent stem cells facilitate the development of stem cell banking. Stem Cells Transl Med 2014; 3: 586-98.
72. Yoo CH, Na HJ, Lee DS, Heo SC, An Y, Cha J, Choi C, Kim JH, Park JC, Cho YS. Endothelial progenitor cells from human dental pulp-derived ips cells as a therapeutic target for ischemic vascular diseases. Biomaterials 2013; 34: 8149-60.
73. Kattman SJ, Witty AD, Gagliardi M, Dubois NC, Niapour M, Hotta A, Ellis J, Keller G. Stage-specific optimization of activin/nodal and BMP signaling promotes cardiac differentiation of mouse and human pluripotent stem cell lines. Cell Stem Cell 2011; 8: 228-40.
74. Gupta DK, Sharma S, Venugopal P, Kumar L, Mohanty S, Dattagupta S. Stem cells as a therapeutic modality in pediatric malformations. Transplant Proc 2007; 39: 700-2.
75. Khan AA, Parveen N, Mahaboob VS, Rajendraprasad A, Ravindraprakash HR, Venkateswarlu J, Rao SG, Narusu ML, Khaja MN, Pramila R, Habeeb A, Habibullah CM. Safety and efficacy of autologous bone marrow stem cell transplantation through hepatic artery for the treatment of chronic liver failure: a preliminary study. Transplant Proc 2008; 40: 1140-4.
76. Malhi H, Annamaneni P, Slehria S, Joseph B, Bhargava KK, Palestro CJ, Novikoff PM, Gupta S. Cyclophosphamide disrupts hepatic sinusoidal endothelium and improves transplanted cell engraftment in rat liver. Hepatology 2002; 36: 112-21.
77. Krause P, Rave-Fränk M, Wolff HA, Becker H, Christiansen H, Koenig S. Liver sinusoidal endothelial and biliary cell repopulation following irradiation and partial hepatectomy. World J Gastroenterol 2010; 16: 3928-35.
78. Amin MT, Shazly SA. In utero stem cell transplantation for radical treatment of osteogenesis imperfecta: perspectives and controversies. Am J Perinatol 2013; 31: 829-36.
79. Götherström C, Westgren M, Shaw SW, Aström E, Biswas A, Byers PH, Mattar CN, Graham GE, Taslimi J, Ewald U, Fisk NM, Yeoh AE, Lin JL, Cheng PJ, Choolani M, Le Blanc K, Chan JK. Pre- and postnatal transplantation of fetal mesenchymal stem cells in osteogenesis imperfecta: a two-center experience. Stem Cells Transl Med 2014; 3: 255-64.
80. Wood JA, Colletti E, Mead LE, Ingram D, Porada CD, Zanjani ED, Yoder MC, Almeida-Porada G. Distinct contribution of human cord blood-derived endothelial colony forming cells to liver and gut in a fetal sheep model. Hepatology 2012; 56: 1086-96.
81. Rosenberg B, Greengard S, Montgomery R. Genetic induction of a releasable pool of factor VIII in human endothelial cells. Arterioscler Thromb Vasc Biol 2000; 20: 2689-95.
82. Aronovich A, Tchorsh D, Katchman H, Eventov-Friedman S, Shezen E, Martinowitz U, Blazar BR, Cohen S, Tal O, Reisner Y. Correction of hemophilia as a proof of concept for treatment of monogenic diseases by fetal spleen transplantation. Proc Natl Acad Sci U S A 2006; 103: 19075-80.
83. Banshodani M, Onoe T, Shishida M, Tahara H, Hashimoto S, Igarashi Y, Tanaka Y, Ohdan H. Adoptive transfer of allogeneic liver sinusoidal endothelial cells specifically inhibits T cell responses to cognate stimuli. Cell Transplant 2012; 22: 1695-708.